Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis
This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis. From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2015-01, Vol.11 (23), p.3159-3166 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3166 |
|---|---|
| container_issue | 23 |
| container_start_page | 3159 |
| container_title | Future oncology (London, England) |
| container_volume | 11 |
| creator | Guida, Annalisa Masini, Cristina Milella, Michele Di Lorenzo, Giuseppe Santoni, Matteo Prati, Veronica Porta, Camillo Cosmai, Laura Donati, Donatella del Giovane, Cinzia Mighali, Pasquale Sabbatini, Roberto |
| description | This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis.
From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected.
Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported.
Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings. |
| doi_str_mv | 10.2217/fon.15.256 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1744664450</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275064595</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-5d37d85fc1fc860a5da656ea6914f7a90977d31455536ebf44798cb9786fab5e3</originalsourceid><addsrcrecordid>eNptkU9rHSEUxaW0NH_aTT5AEbopgXlRx6szyxLaJhAIlGYtPucaDDPOqzoP3ipfvT4m7aJkpR5_HrnnEHLB2UYIrq_8HDccNgLUG3LKtZRN1zL-tu6l7hulenlCznJ-YkzqFth7ciIUSNkLcUqef2JJc96hK2GP1EY7HnLIdI40W4_lUKWBovfBWXegs6e4xzSPYVoyDZGWhLZMGMvxasJic7ElOJqwOlFno8NEd1WqSK6qw7AP8ZEOYf3oA3nn7Zjx48t6Th6-f_t1fdPc3f-4vf5617hWidLA0OqhA--4d51iFgarQKFVPZde2571Wg8tlwDQKtx6WSfv3LbXnfJ2C9ieky-r7y7NvxfMxUwhOxxHG3FesjnGppSUwCr6-T_0aV5SHScbITQwJaGHSl2ulKvx5YTe7FKYbDoYzsyxFlNrMRxMraXCn14sl-2Ewz_0bw8VUCvgl7IkzK7m5dCsp_oiuBDxNec_6zWdfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275064595</pqid></control><display><type>article</type><title>Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis</title><source>MEDLINE</source><source>PubMed Central</source><creator>Guida, Annalisa ; Masini, Cristina ; Milella, Michele ; Di Lorenzo, Giuseppe ; Santoni, Matteo ; Prati, Veronica ; Porta, Camillo ; Cosmai, Laura ; Donati, Donatella ; del Giovane, Cinzia ; Mighali, Pasquale ; Sabbatini, Roberto</creator><creatorcontrib>Guida, Annalisa ; Masini, Cristina ; Milella, Michele ; Di Lorenzo, Giuseppe ; Santoni, Matteo ; Prati, Veronica ; Porta, Camillo ; Cosmai, Laura ; Donati, Donatella ; del Giovane, Cinzia ; Mighali, Pasquale ; Sabbatini, Roberto</creatorcontrib><description>This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis.
From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected.
Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported.
Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon.15.256</identifier><identifier>PMID: 26544922</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Aged ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Cancer therapies ; Carcinoma, Renal Cell - mortality ; Carcinoma, Renal Cell - pathology ; Carcinoma, Renal Cell - therapy ; Combined Modality Therapy ; dialysis ; Drug dosages ; everolimus ; Everolimus - administration & dosage ; Everolimus - adverse effects ; Everolimus - therapeutic use ; Family medical history ; Female ; Hemodialysis ; Humans ; Kaplan-Meier Estimate ; Kidney cancer ; Kidney diseases ; Kidney Neoplasms - mortality ; Kidney Neoplasms - pathology ; Kidney Neoplasms - therapy ; Kinases ; Male ; Medical prognosis ; Metastasis ; metastatic renal cell carcinoma ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Patients ; Protein Kinase Inhibitors - administration & dosage ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Renal Dialysis - methods ; Retrospective Studies ; Treatment Outcome ; Tumors</subject><ispartof>Future oncology (London, England), 2015-01, Vol.11 (23), p.3159-3166</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Dec 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-5d37d85fc1fc860a5da656ea6914f7a90977d31455536ebf44798cb9786fab5e3</citedby><cites>FETCH-LOGICAL-c362t-5d37d85fc1fc860a5da656ea6914f7a90977d31455536ebf44798cb9786fab5e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26544922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guida, Annalisa</creatorcontrib><creatorcontrib>Masini, Cristina</creatorcontrib><creatorcontrib>Milella, Michele</creatorcontrib><creatorcontrib>Di Lorenzo, Giuseppe</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Prati, Veronica</creatorcontrib><creatorcontrib>Porta, Camillo</creatorcontrib><creatorcontrib>Cosmai, Laura</creatorcontrib><creatorcontrib>Donati, Donatella</creatorcontrib><creatorcontrib>del Giovane, Cinzia</creatorcontrib><creatorcontrib>Mighali, Pasquale</creatorcontrib><creatorcontrib>Sabbatini, Roberto</creatorcontrib><title>Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis.
From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected.
Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported.
Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.</description><subject>Aged</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer therapies</subject><subject>Carcinoma, Renal Cell - mortality</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Carcinoma, Renal Cell - therapy</subject><subject>Combined Modality Therapy</subject><subject>dialysis</subject><subject>Drug dosages</subject><subject>everolimus</subject><subject>Everolimus - administration & dosage</subject><subject>Everolimus - adverse effects</subject><subject>Everolimus - therapeutic use</subject><subject>Family medical history</subject><subject>Female</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Kidney cancer</subject><subject>Kidney diseases</subject><subject>Kidney Neoplasms - mortality</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - therapy</subject><subject>Kinases</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>metastatic renal cell carcinoma</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Staging</subject><subject>Patients</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Renal Dialysis - methods</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkU9rHSEUxaW0NH_aTT5AEbopgXlRx6szyxLaJhAIlGYtPucaDDPOqzoP3ipfvT4m7aJkpR5_HrnnEHLB2UYIrq_8HDccNgLUG3LKtZRN1zL-tu6l7hulenlCznJ-YkzqFth7ciIUSNkLcUqef2JJc96hK2GP1EY7HnLIdI40W4_lUKWBovfBWXegs6e4xzSPYVoyDZGWhLZMGMvxasJic7ElOJqwOlFno8NEd1WqSK6qw7AP8ZEOYf3oA3nn7Zjx48t6Th6-f_t1fdPc3f-4vf5617hWidLA0OqhA--4d51iFgarQKFVPZde2571Wg8tlwDQKtx6WSfv3LbXnfJ2C9ieky-r7y7NvxfMxUwhOxxHG3FesjnGppSUwCr6-T_0aV5SHScbITQwJaGHSl2ulKvx5YTe7FKYbDoYzsyxFlNrMRxMraXCn14sl-2Ewz_0bw8VUCvgl7IkzK7m5dCsp_oiuBDxNec_6zWdfw</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Guida, Annalisa</creator><creator>Masini, Cristina</creator><creator>Milella, Michele</creator><creator>Di Lorenzo, Giuseppe</creator><creator>Santoni, Matteo</creator><creator>Prati, Veronica</creator><creator>Porta, Camillo</creator><creator>Cosmai, Laura</creator><creator>Donati, Donatella</creator><creator>del Giovane, Cinzia</creator><creator>Mighali, Pasquale</creator><creator>Sabbatini, Roberto</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150101</creationdate><title>Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis</title><author>Guida, Annalisa ; Masini, Cristina ; Milella, Michele ; Di Lorenzo, Giuseppe ; Santoni, Matteo ; Prati, Veronica ; Porta, Camillo ; Cosmai, Laura ; Donati, Donatella ; del Giovane, Cinzia ; Mighali, Pasquale ; Sabbatini, Roberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-5d37d85fc1fc860a5da656ea6914f7a90977d31455536ebf44798cb9786fab5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer therapies</topic><topic>Carcinoma, Renal Cell - mortality</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Carcinoma, Renal Cell - therapy</topic><topic>Combined Modality Therapy</topic><topic>dialysis</topic><topic>Drug dosages</topic><topic>everolimus</topic><topic>Everolimus - administration & dosage</topic><topic>Everolimus - adverse effects</topic><topic>Everolimus - therapeutic use</topic><topic>Family medical history</topic><topic>Female</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Kidney cancer</topic><topic>Kidney diseases</topic><topic>Kidney Neoplasms - mortality</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - therapy</topic><topic>Kinases</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>metastatic renal cell carcinoma</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Staging</topic><topic>Patients</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Renal Dialysis - methods</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guida, Annalisa</creatorcontrib><creatorcontrib>Masini, Cristina</creatorcontrib><creatorcontrib>Milella, Michele</creatorcontrib><creatorcontrib>Di Lorenzo, Giuseppe</creatorcontrib><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Prati, Veronica</creatorcontrib><creatorcontrib>Porta, Camillo</creatorcontrib><creatorcontrib>Cosmai, Laura</creatorcontrib><creatorcontrib>Donati, Donatella</creatorcontrib><creatorcontrib>del Giovane, Cinzia</creatorcontrib><creatorcontrib>Mighali, Pasquale</creatorcontrib><creatorcontrib>Sabbatini, Roberto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guida, Annalisa</au><au>Masini, Cristina</au><au>Milella, Michele</au><au>Di Lorenzo, Giuseppe</au><au>Santoni, Matteo</au><au>Prati, Veronica</au><au>Porta, Camillo</au><au>Cosmai, Laura</au><au>Donati, Donatella</au><au>del Giovane, Cinzia</au><au>Mighali, Pasquale</au><au>Sabbatini, Roberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>11</volume><issue>23</issue><spage>3159</spage><epage>3166</epage><pages>3159-3166</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>This retrospective study aimed to investigate safety and efficacy of everolimus in patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease requiring dialysis.
From November 2009 to December 2012, 11 mRCC patients undergoing dialysis were treated with everolimus after failure of anti-VEGF therapy at six Italian institutions. Patient characteristics, safety and outcomes were collected.
Progression-free survival and overall survival were determined using the Kaplan-Meier method. Median progression-free survival and overall survival were 9.01 and 15.7 months, respectively. No unexpected adverse events were reported.
Everolimus appears to be safe in mRCC patients with renal impairment or end-stage renal disease requiring dialysis. Larger prospective studies are required to confirm these findings.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>26544922</pmid><doi>10.2217/fon.15.256</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2015-01, Vol.11 (23), p.3159-3166 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1744664450 |
| source | MEDLINE; PubMed Central |
| subjects | Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - therapy Combined Modality Therapy dialysis Drug dosages everolimus Everolimus - administration & dosage Everolimus - adverse effects Everolimus - therapeutic use Family medical history Female Hemodialysis Humans Kaplan-Meier Estimate Kidney cancer Kidney diseases Kidney Neoplasms - mortality Kidney Neoplasms - pathology Kidney Neoplasms - therapy Kinases Male Medical prognosis Metastasis metastatic renal cell carcinoma Middle Aged Neoplasm Metastasis Neoplasm Staging Patients Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Renal Dialysis - methods Retrospective Studies Treatment Outcome Tumors |
| title | Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A20%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retrospective%20analysis%20on%20safety%20and%20efficacy%20of%20everolimus%20in%20treatment%20of%20metastatic%20renal%20cancer%20patients%20receiving%20dialysis&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Guida,%20Annalisa&rft.date=2015-01-01&rft.volume=11&rft.issue=23&rft.spage=3159&rft.epage=3166&rft.pages=3159-3166&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon.15.256&rft_dat=%3Cproquest_cross%3E2275064595%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2275064595&rft_id=info:pmid/26544922&rfr_iscdi=true |